MedTrace Logo

Evaluate Analgesic Efficacy of Fast Release Aspirin

NCT01122602 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2018-12-19

No results posted yet for this study

Summary

The objective of the study is to evaluate the analgesic efficacy of a single, oral dose of fast release aspirin tablets, 650 mg (2 x 325 mg) compared to regular aspirin tablets, 650 mg (2 x 325 mg) and placebo in subjects with postsurgical dental pain.

Conditions

  • Drugs, Investigational

Interventions

DRUG

Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)

Single dose of fast acting aspirin 2 x 325 mg = 650 mg total

DRUG

Acetylsalicyclic acid (Aspirin, BAYE4465)

Single dose of regular aspirin 2 x 325 mg = 650 mg total

DRUG

Placebo

Two placebo tablets

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-29
Primary Completion
2010-07-29
Completion
2010-08-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01122602 on ClinicalTrials.gov